title: Transport and processing of beta-hexosaminidase in normal and mucolipidosis-II cultured fibroblasts. Effect of monensin and nigericin.
abstract: The univalent-cation ionophores monensin (4.0 microM) and nigericin (0.5 microM) inhibited the abnormal excretion of beta-hexosaminidase from mucolipidosis-II cultured fibroblasts by 62 and 76% respectively, with a corresponding intracellular accumulation of the enzyme. As shown by lectin binding, the enzyme which accumulated in monensin-treated cells did not contain galactose residues, whereas the corresponding enzyme from nigericin-treated cells was galactosylated. The results suggest that monensin acts at an early point in the process of hydrolase glycosylation, and nigericin acts later, both presumably within the Golgi region, allowing the accumulation of different glycosylated forms of the enzyme. The intra- and extra-cellular distribution of beta-hexosaminidase in ionophore-treated normal cells was essentially unchanged, whereas concanavalin A precipitability of excreted enzyme was increased and its ability to be taken up by deficient fibroblasts was decreased. The bivalent-cation ionophore A23187 (1 microM) reduced beta-hexosaminidase excretion from mucolipidosis-II cells by 82% and by 96% when used with EGTA (1 mM). However, there was no intracellular accumulation of enzyme, suggesting that the effect of this ionophore was restricted to the inhibition of synthesis. It therefore appears that the actual transport of beta-hexosaminidase in mucolipidosis-II cells is affected by univalent-cation ionophores in a selective manner. These findings suggest that individual ionophores could be used to identify the sites of hydrolase oligosaccharide processing in the Golgi region by causing intermediate glycosylated forms of the transported hydrolase to accumulate in a specific Golgi compartment preceding the blocking site of the ionophore.
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D003208:Concanavalin A / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology*; D005663:Furans / Q000494:pharmacology*; D006596:Hexosaminidases / Q000378:metabolism*; D006801:Humans; D008985:Monensin / Q000494:pharmacology*; D009081:Mucolipidoses / Q000201:enzymology*; D009550:Nigericin / Q000494:pharmacology*; D012276:Ricin / Q000378:metabolism; D001619:beta-N-Acetylhexosaminidases
chemical_list: D000900:Anti-Bacterial Agents; D005663:Furans; D003208:Concanavalin A; D000001:Calcimycin; D012276:Ricin; D008985:Monensin; D006596:Hexosaminidases; D001619:beta-N-Acetylhexosaminidases; D009550:Nigericin